Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4
Therapy Versus High-Dose Interferon a-2b for Resected High-risk
Open to completely resected melanoma.
Pts must be randomized w/in 84 days of surgical resection
No previous chemotherapy allowed
Previous irradiation is allowed as long as 30 days have elapsed prior to study start